World Health Matters: Germany: Concern over hepatitis B among refugees
by Gary Finnegan: People seeking refuge and asylum in Germany are at higher risks of liver problems due to hepatitis B, according to experts.
by Gary Finnegan: People seeking refuge and asylum in Germany are at higher risks of liver problems due to hepatitis B, according to experts.
by Bruce Sylvester: Pioglitazone shows efficacy against the progression of nonalcoholic steatohepatitis, or NASH, a chronic liver disease caused by a buildup of fat. Researchers reported this finding… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Feature Symposium. Stephen Strom, Karolinska Institutet, Stockholm, Sweden. Luc van der Laan, Erasmus Medical Center, Rotterdam, the Netherlands. Alberto Sanchez-Fueyo, King’s College Hospital, London, UK. David Hay, University… read more.
Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014. Recurrence of hepatitis C virus (HCV) infection after transplantation is a major challenge for centres all… read more.
Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014. Roger Williams, Institute of Hepatology/Foundation for Liver Research, London, UK. Medical care after acute liver failure… read more.
Re-transplantation is the only option available for salvaging a failed abdominal graft. As the outcomes after primary transplantations continue to improve, even with the increasing use of extended-criteria… read more.
by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
C. difficile is a bacterium that is common in the environment. According to the Center for Disease Control and Prevention, approximately 337,000 cases of CDI are reported each… read more.
by Thomas R. Collins – The state of treatment for Hepatitis C patients waiting for a liver transplant leaves a lot to be desired
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.